Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data.The biotech’s pyruvate kinase activator tebapivat did not meet the company’s 'predefined threshold' for continued development in the study.
May 29, 2026 10:50 AM EDT
Agios ends development of tebapivat in low-risk MDS following subpar results
Ayisha Sharma
News Reporter
Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b …
Allogene CEO to step down; Agios drug fails key test
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease - Pharmaceutical Technology
Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful…
Agios' PK activator tebapivat looked no better than the first-generation agents in sickle cell disease, although it's awaiting…
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated…
Agios Pharma (AGIO) stock spikes 15% as FDA grants Priority Review for sickle cell disease drug mitapivat. Details here.
Agios licenses Oscotec’s immune thrombocytopenia drug; CEPI funds three Ebola vaccine candidates; Skyhawk shares Huntington's…
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
